Europe's most promising health innovators are racing to solve some of medicine's thorniest problems, from detecting sepsis in hours instead of days to using artificial intelligence to identify rare diseases that doctors typically miss. The EIT Health Catapult, a flagship European competition and training program, has selected 30 high-potential startups for its 10th edition, marking a significant milestone in how the continent is accelerating healthcare innovation.

The competition represents a carefully curated snapshot of where health technology is heading. Over the past decade, EIT Health Catapult has supported more than 300 startups, helping them gain visibility, credibility, and access to investors as they scale innovative healthcare solutions across Europe and beyond. The 30 semifinalists selected this year were chosen from a highly competitive pool of applicants, each demonstrating exceptional potential to transform healthcare through innovations in life sciences, medical technology, and digital health.

What Makes These Startups Different From Traditional Medical Innovation?

To qualify for the Catapult program, companies must meet strict criteria: they must be incorporated and operating in an EU Member State or Horizon Europe country, have fewer than 50 employees, have secured at least 500,000 euros in private investment or generated that much in revenue during the previous year, and be seeking funding of at least 2 million euros. This filtering process ensures that only the most serious, well-funded ventures make the cut.

The selection process itself is rigorous. Applications were assessed by experts from across the EIT Health network against three key evaluation pillars: the quality and innovation of the technology or solution, the potential to address healthcare challenges and improve patient outcomes, and the strength of the business model, team, and growth strategy. This multi-dimensional approach means the startups advancing aren't just technically clever; they also have realistic paths to market and genuine potential to help patients.

How Are AI and Diagnostics Reshaping Patient Care?

Several of the selected startups are using artificial intelligence to solve diagnostic challenges that have stumped traditional medicine for years. Lunarchy Teknoloji, based in Spain, has built a decision support tool that helps physicians identify rare diseases earlier by turning complex medical data into clear insights, improving patients' access to the right care sooner. This addresses a critical gap: rare disease patients often wait years for a correct diagnosis, during which time their condition can worsen significantly.

Loop Diagnostics, also from Spain, is developing rapid blood tests that help doctors identify severe bacterial infections and sepsis earlier, enabling faster treatment and improving patient outcomes. Early sepsis detection is literally a matter of life and death; every hour of delay in treatment increases mortality risk substantially. Similarly, Levels Diagnostics from the Netherlands is developing a test to identify liver cancer when it is still curable in at-risk patients suffering from advanced liver damage, or cirrhosis.

Beyond diagnostics, AI is being deployed to support clinical decision-making in real time. Strive Health, a United Kingdom startup, has built an AI system that learns from millions of past cases to guide doctors in real time when treating the sickest patients, adapting treatment as patient physiology evolves. This represents a fundamental shift in how AI can augment physician expertise rather than replace it.

What Breakthrough Therapies Are These Startups Developing?

The therapeutic innovations span multiple disease areas, reflecting the diversity of unmet medical needs across Europe. Several startups are tackling autoimmune and inflammatory diseases with novel approaches:

• Immune System Retraining: Diamante, based in Italy, is developing a short, one-course therapy that retrains the immune system to stop rheumatoid arthritis at its earliest stage, before joint damage occurs, potentially eliminating the need for lifelong medication.
• Targeted Immune Modulation: FcR Therapeutics from the Netherlands develops new medicines to calm harmful immune reactions in autoimmune diseases, where the body attacks itself.
• Non-Opioid Pain Management: Akasi Pharma from Denmark is developing a new, non-opioid weekly injection to treat chronic nerve pain in diabetes patients, without the addiction risk or side effects of current options.

Cancer treatment is another major focus area. Oniria Therapeutics from Spain is developing a novel oral medicine that helps the body fight cancer by restoring its natural protective mechanisms and reducing the risk of tumor recurrence. Panosome, based in Germany, develops antibodies against cancer markers that existing therapies cannot reach, creating new treatment opportunities for patients with hard-to-treat cancers such as pancreatic and ovarian cancer. OvartiX from the United Kingdom is building the first drug discovery platform specifically for women's health, with its first asset, OVX001, designed for preventing medically induced premature menopause in cancer patients.

How Are Medical Devices and Monitoring Technologies Advancing?

Beyond pharmaceuticals and diagnostics, the selected startups include several medical device companies addressing gaps in patient monitoring and surgical precision. Bios Medical from Switzerland is developing the world's first implanted hip mobility sensor to track recovery progress in real time, giving surgeons and patients concrete data on healing rather than guesswork. CLARO Surgical from the United Kingdom is modernizing orthopedic surgery itself; the company notes that 170 million broken bones are still operated on each year using techniques from the 1940s, with no X-rays and significant guesswork involved. CLARO is bringing orthopedic surgery into the 21st century.

Other device innovations address critical safety and monitoring gaps. Sencilia from the Netherlands is developing Rely-V, a first-of-its-kind intravenous infusion monitoring sensor designed to prevent dangerous medication errors in fragile newborns. Metyos from France is building the first wearable patch that catches sudden potassium imbalances in heart and kidney patients early, treating the danger before it strikes; these imbalances can take lives within hours with no warning. Heecap from Spain has created a smart, non-invasive device that keeps breathing muscles active for intensive care unit patients on ventilators, preventing muscle atrophy and helping them recover faster.

What Do These Startups Tell Us About Healthcare's Future?

The diversity of solutions among the 30 semifinalists reveals several emerging trends in healthcare innovation. First, there is a clear shift toward precision medicine and personalization. Solid IO from Finland personalizes cancer immunotherapy, helping more patients receive treatments that are likely to work. TimeTeller from Germany is pioneering circadian diagnostics, using saliva biomarkers and artificial intelligence to identify the optimal biological time for treatment to improve outcomes, reduce toxicity, and personalize healthcare.

Second, administrative burden and clinician burnout are being addressed directly. Aiomics from Germany turns the unstructured documents a hospital drowns in into a verified patient record, then runs operational and compliance workflows from it, giving clinicians back the time lost to paperwork. Omniloy from Spain builds AI agents that transform healthcare delivery by supporting clinical decision-making, reducing administrative workload, and improving patient access and experience. These solutions recognize that modern healthcare workers are overwhelmed not just by patient care but by documentation and compliance tasks.

Third, regenerative medicine and cell therapy are advancing. NurExone Biologic, a Canada and Israel-based company, develops innovative exosome-based therapies to repair and regenerate nerve cells, offering hope for patients with central nervous system injuries and disorders. Provasctec from Ireland aims to expand the application of cell therapies through precision delivery of cells, with its lead product providing treatment for patients with critical limb ischemia, a condition with few options.

The selection of these 30 startups demonstrates that European health innovation is increasingly focused on solving real, specific problems rather than chasing broad technological trends. Over the upcoming months, these companies will benefit from tailored training, expert mentoring, and investor exposure as they compete for a place among the finalists of this 10th anniversary landmark edition. For investors, healthcare systems, and patients watching these developments, the Catapult cohort offers a window into which innovations are likely to reshape clinical practice in the next five to ten years.